Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Abstract Text:

Robert E Vann,John A Rosecrans,John R James,Scott D Philibin,Susan E Robinson,

The primary mechanism of action of bupropion, a smoking cessation drug, is commonly believed to involve the dopaminergic system although evidence exists that bupropion also has effects at nicotinic acetylcholine receptors (nAChRs). This study evaluated the disruptive effects of nicotine on response rates in the presence of bupropion and the nAChR antagonist, mecamylamine, as well as the ability of these drugs to alter nicotine-stimulated nAChR function in various brain areas. Rats were trained to respond on a single lever under a variable interval 15 (VI15) schedule for food reinforcement. Initially, dose effect curves were generated for nicotine, bupropion and mecamylamine. Upon determining the dose of nicotine (1.2 mg/kg) effective in completely disrupting rates of responding, it was established that both mecamylamine and bupropion block nicotine's rate-reducing effects. This result suggests that bupropion shares behavioral effects with mecamylamine when administered in the presence of nicotine. To explore this relationship further, the effect of in vivo administration of bupropion or mecamylamine on nicotine-stimulated (86)Rb(+) efflux was studied in synaptosomes prepared from the frontal cortex, hippocampus, striatum and thalamus. Nicotine-stimulated (86)Rb(+) efflux from all brain regions was significantly reduced in rats administered 3.0 mg/kg mecamylamine (s.c.) 15 min prior to dissection compared to control rats. In contrast, a significant increase in nicotine-stimulated (86)Rb(+) efflux was observed in all brain regions from rats administered 30.0 mg/kg bupropion (s.c.) 15 min prior to dissection compared to control rats. Taken together these results demonstrate that when administered in the presence of nicotine, bupropion elicits unique pharmacological differences such that it exhibits both nAChR agonist- and antagonistic-like effects.

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Publishing Authors By Initials

RE Vann,JA Rosecrans,JR James,SD Philibin,SE Robinson,

For similar disorders of environmental origin: substance-related disorders: tobacco use disorder research abstracts see: disorders of environmental origin: substance-related disorders: tobacco use disorder research

PUBMED ID PMID:

MEDLINE DATE:

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Brain research

VOLUME: 1117

Page Numbers: 18-24

Journal Abbreviation: Brain Res.

ISSN: 0006-8993

DAY: 1

MONTH: 09

YEAR: 2006

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 45503

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Keywords Mesh Terms:

KEYWORDS: Tobacco Use Disorder

MESH TERMS: physiopathology

Chemical & Substance for Abstract: Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine. Information

Substance Name: Mecamylamine

Registry Number: 60-40-2

Grant and Affiliation Information for Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.

AFFILIATION: Department of Pharmacology, Virginia Commonwealth University, Richmond, PO Box 980613, Richmond, VA 23298-0613, USA. revann@vcu.edu

Country: Netherlands

AGENCY: United States NIDA

GRANT: DA-019377

ACRONYM: DA

MEDLINETA: Brain Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine Related Publications

• A basic program to determine outliers in biopharmaceutical analysis using the Nair criterion.
• Asymmetric fraunhofer diffraction from roller-blade slits.
• Co-localization of glycine and gaba immunoreactivity in interneurons in Macaca monkey cerebellar cortex.
• Comparative three-dimensional imaging of living neurons with confocal and atomic force microscopy.
• Detection of problem-drinkers in an emergency department using a breathalyser and questionnaire.
• Effects of intrauterine challenge with Leptospira interrogans serovar hardjo on fertility in cattle.
• Explanation of spin-lattice relaxation rates of spin labels obtained with multifrequency saturation recovery EPR.
• Geographic Information Systems and the Selection of Priority Areas for Control of Tsetse-transmitted Trypanosomiasis in Africa.
• HPLC procedure for the determination of some potential fluphenazine metabolites in urine.
• Identification of enzymatic degradation products of luteinizing hormone releasing hormone (LHRH)/[D-Ala6] LHRH in rabbit mucosal homogenates.
• Mitosis-specific mechanosensing and contractile-protein redistribution control cell shape.
• Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins.
• Monoamine oxidase inhibitors: a new generation.
• Mortality of intravenous drug users: attenders of the Wellington Drug Clinic, 1972-89.
• Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.
• Oral neoplasms of children.
• Pinealectomy does not affect diurnal PER2 expression in the rat limbic forebrain.
• Protein kinase C-dependent remodeling of glutamate transporter function.
• Public and private intervention rates in obstetric practice.
• Pulmonary tuberculosis: the primary lesion; specific vs. nonspecific therapy.
• Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
• Spotlight on pioglitazone in type 2 diabetes mellitus.
• Syndapin I is the phosphorylation-regulated dynamin I partner in synaptic vesicle endocytosis.
• Technology can't replace compassion in health care.
• The absence of adaptive changes in tissue activities of glutathione-S-transferase, superoxide dismutase and catalase following selenium and vitamin E supplementation in subjects with low selenium status.
• The determination of nadolol in biological samples using high-performance liquid chromatography.
• The short-lived exostosis induced surgically versus the lasting genetic hereditary multiple exostoses.
• The truth about colorectal cancer.
• The use of complementary and alternative therapies in dogs and cats with cancer.
• Vitamin E improves cell-mediated immunity in the burned mouse: a preliminary study.